
Michel Henry-Amar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6872850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Economic burden in nonâ€Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2021, , .	4.1	1
2	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. Health and Quality of Life Outcomes, 2019, 17, 115.	2.4	13
3	Longâ€ŧerm fatigue in survivors of nonâ€Hodgkin lymphoma: The Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2019, 125, 2291-2299.	4.1	14
4	Comparison of 36ÂGy, 20ÂGy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1133-1145.	0.8	21
5	Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial Journal of Clinical Oncology, 2018, 36, TPS530-TPS530.	1.6	2
6	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. European Journal of Cancer, 2017, 81, 45-55.	2.8	33
7	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica, 2017, 102, 1748-1757.	3.5	38
8	Differential distribution of <i>vapA</i> â€positive <i>Rhodococcus equi</i> in affected and unaffected horseâ€breeding farms. Veterinary Record, 2017, 181, 145-145.	0.3	2
9	Does persistent fatigue in survivors relate to cancer?. Lancet Oncology, The, 2016, 17, 1351-1352.	10.7	6
10	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study Journal of Clinical Oncology, 2016, 34, 7518-7518.	1.6	1
11	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematology,the, 2015, 2, e492-e502.	4.6	123
12	Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Human Reproduction, 2014, 29, 525-533.	0.9	30
13	Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study. Journal of Clinical Oncology, 2012, 30, 291-299.	1.6	99
14	Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. Journal of Clinical Oncology, 2012, 30, 3854-3863.	1.6	32
15	One-Year Longitudinal Study of Fatigue, Cognitive Functions, and Quality of Life After Adjuvant Radiotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 795-803.	0.8	86
16	Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Research and Treatment, 2011, 129, 125-134.	2.5	89
17	Health-Related Quality of Life Among Long-Term Survivors of Colorectal Cancer: A Population-Based Study. Oncologist, 2011, 16, 1626-1636.	3.7	82
18	Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial. Gynecologic Oncology, 2010, 116, 312-316.	1.4	6

#	Article	IF	CITATIONS
19	Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica, 2009, 94, 1691-1697.	3.5	80
20	Clinical Relevance of Single-Photon Emission Computed Tomography/Computed Tomography of the Neck and Thorax in Postablation 1311 Scintigraphy for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2075-2084.	3.6	104
21	Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study. Gynecologic Oncology, 2009, 115, 382-388.	1.4	6
22	Survival after Hodgkin lymphoma. Cancer, 2009, 115, 1680-1691.	4.1	72
23	Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clinical Endocrinology, 2009, 71, 880-883.	2.4	11
24	Low-Dose Involved-Field Radiotherapy as Alternative Treatment of Nodular Lymphocyte Predominance Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1199-1202.	0.8	19
25	Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clinical Genitourinary Cancer, 2009, 7, E28-E33.	1.9	43
26	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial. Lancet Oncology, The, 2009, 10, 1160-1170.	10.7	96
27	Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histology and Histopathology, 2009, 24, 425-35.	0.7	12
28	Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiotherapy and Oncology, 2008, 87, 164-172.	0.6	37
29	Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma European Journal of Endocrinology, 2008, 158, 551-560.	3.7	164
30	Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 2007, 25, 2825-2832.	1.6	96
31	Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Human Pathology, 2007, 38, 212-219.	2.0	109
32	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. New England Journal of Medicine, 2007, 357, 1916-1927.	27.0	412
33	Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 19-30.	0.8	71
34	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology, 2006, 17, 1749-1760.	1.2	171
35	Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Annals of Oncology, 2006, 17, 141-145.	1.2	28
36	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. Journal of Clinical Oncology, 2006, 24, 3128-3135.	1.6	216

#	Article	IF	CITATIONS
37	Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC) Tj ETÇ	2q1,1,0.78	34314 rgBT 22
38	Expression of α V-associated integrin β subunits in epithelial ovarian cancer andits relation to prognosis in patients treated with platinum-based regimens. Journal of Molecular Histology, 2005, 36, 119-129.	2.2	27
39	Radiotherapy in Advanced-Stage Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 245-246.	1.6	1
40	Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial Blood, 2005, 106, 813-813.	1.4	23
41	Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial Blood, 2005, 106, 814-814.	1.4	46
42	Risk of second primary cancer following differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 685-691.	6.4	79
43	Urine mutagenicity of farmers occupationally exposed during a 1-day use of chlorothalonil and insecticides. International Archives of Occupational and Environmental Health, 2003, 76, 55-62.	2.3	11
44	Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma. Cancer, 2003, 97, 1376-1386.	4.1	29
45	BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: Lack of seasonal variations in frequency and molecular features. International Journal of Cancer, 2003, 104, 695-698.	5.1	17
46	Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. New England Journal of Medicine, 2003, 348, 2396-2406.	27.0	301
47	Urine mutagenicity and lymphocyte DNA damage in fruit growers occupationally exposed to the fungicide captan. Occupational and Environmental Medicine, 2003, 60, 910-917.	2.8	31
48	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood, 2003, 103, 1222-1228.	1.4	140
49	Biomonitoring of urine mutagenicity with the Ames test: improvement of the extraction/concentration method. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 520, 199-205.	1.7	10
50	The achievements of the EORTC Lymphoma Group. European Journal of Cancer, 2002, 38, 107-113.	2.8	64
51	Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 380-387.	6.4	21
52	Hodgkins disease. British Journal of Cancer, 2001, 84, 55-60.	6.4	5
53	Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial. Cancer, 2000, 89, 1748-1757.	4.1	38
54	Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 176-184.	6.4	40

#	Article	IF	CITATIONS
55	Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. British Journal of Cancer, 2000, 82, 263-269.	6.4	89
56	Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. British Journal of Cancer, 2000, 83, 577-582.	6.4	69
57	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. Journal of Clinical Oncology, 1999, 17, 222-222.	1.6	147
58	Late Clonal Complications in Older Patients Receiving Immunosuppressive Therapy for Aplastic Anemia. Annals of Internal Medicine, 1999, 131, 633.	3.9	0
59	Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia. Annals of Internal Medicine, 1999, 130, 193.	3.9	97
60	DNA damaging effects of pesticides measured by the single cell gel electrophoresis assay (comet assay) and the chromosomal aberration test, in CHOK1 cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1998, 419, 79-90.	1.7	52
61	Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Annals of Oncology, 1998, 9, 751-757.	1.2	86
62	Assessment of DNA damage induced in vitro by etoposide and two fungicides (carbendazim and) Tj ETQq0 0 0 Molecular Mechanisms of Mutagenesis, 1997, 375, 205-217.) rgBT /Overl 1.0	ock 10 Tf 50 62
63	A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis. International Journal of Radiation Oncology Biology Physics, 1997, 38, 163-168.	0.8	11
64	Descriptive epidemiology of cerebral gliomas in France. Cancer, 1997, 79, 1195-1202.	4.1	114
65	Title is missing!. Annals of Oncology, 1997, 8, 111-114.	1.2	16
66	Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group Journal of Clinical Oncology, 1996, 14, 869-877.	1.6	558
67	Late psychosocial sequelae in Hodgkin's disease survivors: a French population-based case-control study Journal of Clinical Oncology, 1996, 14, 2444-2453.	1.6	125
68	10 Treatment sequelae and quality of life. Best Practice and Research: Clinical Haematology, 1996, 9, 595-618.	1.1	6
69	Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. British Journal of Haematology, 1996, 93, 731-736.	2.5	213
70	Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers, 1996, 1, 226-231.	1.9	4
71	ls neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?. European Journal of Cancer, 1995, 31, 307-314.	2.8	70
72	Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiotherapy and Oncology, 1995, 36, 211-217.	0.6	65

#	Article	IF	CITATIONS
73	A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial Journal of Clinical Oncology, 1994, 12, 279-287.	1.6	102
74	Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1466-1470.	5.6	112
75	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994, 73, 2680-2686.	4.1	1,719
76	Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiotherapy and Oncology, 1994, 30, 55-58.	0.6	25
77	Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. International Journal of Cancer, 1993, 54, 60-67.	5.1	7
78	Follow-up thallium-201 scintigraphy after mantle field radiotherapy for hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1993, 25, 871-876.	0.8	23
79	Linitis plastica after Hodgkin's disease. Lancet, The, 1993, 342, 57-58.	13.7	10
80	Malignant Tumors Occurring after Treatment of Aplastic Anemia. New England Journal of Medicine, 1993, 329, 1152-1157.	27.0	445
81	Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols Journal of Clinical Oncology, 1993, 11, 225-232.	1.6	43
82	Acute Leukemia After the Treatment of Hodgkin's Disease. Hematology/Oncology Clinics of North America, 1993, 7, 369-387.	2.2	62
83	Osteosarcoma: chemotherapy-induced changes at MR imaging Radiology, 1992, 182, 839-844.	7.3	116
84	Poor Clinical Outcome of Patients Developing Malignant Solid Tumors after Bone Marrow Transplantation for Severe Aplastic Anemia. Leukemia and Lymphoma, 1992, 7, 419-423.	1.3	23
85	The EORTC trials for limited stage Hodgkin's disease. European Journal of Cancer, 1992, 28, 1847-1850.	2.8	64
86	Does malignant small round cell tumor of the thoracopulmonary region (askin tumor) constitute a clinicopathologic entity?. An analysis of 30 cases with immunohistochemical and electron-microscopic support treated at the institute gustave roussy. Cancer, 1992, 69, 1012-1020.	4.1	86
87	Specific Controversies Concerning the Natural History of Renal Disease in Pregnancy. American Journal of Kidney Diseases, 1991, 17, 116-122.	1.9	67
88	Management of relapse and survival in advanced stage Hodgkin's disease: The EORTC experience. Annals of Oncology, 1991, 2, 63-66.	1.2	19
89	Alternating chemotherapy and radiotherapy combination for bulky stage I and II intermediate and high grade non-Hodgkin lymphoma: an update. Radiotherapy and Oncology, 1991, 20, 30-37.	0.6	12
90	Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. Annals of Oncology, 1991, 2, 77-82.	1.2	88

#	Article	IF	CITATIONS
91	Erythrocyte Sedimentation Rate Predicts Early Relapse and Survival in Early-Stage Hodgkin Disease. Annals of Internal Medicine, 1991, 114, 361-365.	3.9	86
92	Pericarditis and myocardial infarctions after Hodgkin's disease therapy. International Journal of Radiation Oncology Biology Physics, 1991, 21, 447-449.	0.8	129
93	Therapeutic implications and sites of relapse predicted by elevated posttherapy erythrocyte sedimentation rate in early stage Hodgkin disease. American Journal of Hematology, 1991, 37, 253-257.	4.1	8
94	Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1155-1157.	0.8	100
95	Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly Journal of Clinical Oncology, 1990, 8, 272-279.	1.6	248
96	Leukemia Following Hodgkin's Disease. New England Journal of Medicine, 1990, 322, 7-13.	27.0	486
97	High Doses of Inhaled Corticosteroids in Unstable Chronic Asthma: A Multicenter, Double-blind, Placebo-controlled Study. The American Review of Respiratory Disease, 1989, 140, 167-171.	2.9	85
98	Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer, 1989, 64, 1208-1217.	4.1	142
99	Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: A review of 312 cases in a controlled clinical trial. European Journal of Cancer & Clinical Oncology, 1989, 25, 551-556.	0.7	18
100	Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: Emphasis on the role of exploratory laparotomy and fractionation. Radiotherapy and Oncology, 1988, 13, 61-68.	0.6	58
101	Lymphoblastic lymphoma in adults: a clinicopathological study of 34 cases treated at the Institut Gustave-Roussy. European Journal of Cancer & Clinical Oncology, 1988, 24, 1609-1616.	0.7	16
102	Late Toxicity of Radiotherapy in Hodgkin's Disease—The Role of Fraction Size. Acta Oncológica, 1988, 27, 123-129.	1.8	76
103	Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease Journal of Clinical Oncology, 1988, 6, 596-602.	1.6	39
104	Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors Journal of Clinical Oncology, 1988, 6, 239-252.	1.6	160
105	Rationale for ACE Inhibition in the Elderly: Treatment of Arterial Hypertension with Enalapril. Gerontology, 1987, 33, 9-16.	2.8	7
106	Pregnancy in IgA Nephropathy, Reflux Nephropathy, and Focal Glomerular Sclerosis. American Journal of Kidney Diseases, 1987, 9, 334-338.	1.9	41
107	Aberrant breakpoints in chronic myelogenous leukaemia; oncogenes and fragile sites. Human Genetics, 1986, 74, 447-448.	3.8	17
108	Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. Virchows Archiv A, Pathological Anatomy and Histopathology, 1986, 409, 627-640.	1.4	38

#	Article	IF	CITATIONS
109	Effects of Infused Intralipids on Neutrophil Chemotaxis during Total Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 1986, 10, 596-598.	2.6	24
110	A multivariate analysis of prognostic factors in early stage hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1985, 11, 23-30.	0.8	138
111	An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: Feasibility and preliminary results. Radiotherapy and Oncology, 1985, 3, 133-138.	0.6	23
112	Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease Journal of Clinical Oncology, 1984, 2, 194-200.	1.6	65
113	Rotavirus Carriage, Asymptomatic Infection, and Disease in the First Two Years of Life. II. Serological Response. Journal of Infectious Diseases, 1984, 149, 675-682.	4.0	52
114	Pulmonary evaluation of patients with osteosarcoma: roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. American Journal of Roentgenology, 1984, 143, 519-523.	2.2	75
115	Rotavirus Carriage, Asymptomatic Infection, and Disease in the First Two Years of Life. I. Virus Shedding. Journal of Infectious Diseases, 1984, 149, 667-674.	4.0	98
116	The EORTC treatment of early stages of hodgkin's disease: The role of radiotherapy. International Journal of Radiation Oncology Biology Physics, 1984, 10, 197-210.	0.8	84
117	Radiation injurie of the gastrointestinal tract in Hodgkin's disease: The role of exploratory laparotomy and fractionation. Radiotherapy and Oncology, 1984, 2, 93-99.	0.6	33
118	Polyploid megakaryocytes develop randomly from a multicompartmental system of committed progenitors Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 4410-4414.	7.1	40
119	Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. European Journal of Cancer, 1981, 17, 355-363.	0.9	74
120	Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. European Journal of Cancer, 1979, 15, 645-657.	0.9	62
121	Therapeutic controlled trial in Ewing's sarcoma. European Journal of Cancer, 1977, 13, 1019-1023.	0.9	22